Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.332 |
---|---|
High | 0.3385 |
Low | 0.332 |
Bid | 0.331 |
Offer | 0.3455 |
Previous close | 0.3285 |
Average volume | 1.33k |
---|---|
Shares outstanding | 15.37m |
Free float | 15.05m |
P/E (TTM) | -- |
Market cap | 5.55m USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Nov 13 2024 16:26 GMT.
More ▼
- Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
More ▼